The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
TU round about 8th or 9th April -
Sp has fallen from 240s but RFX on PE (f) = 10, that's just too cheap.
Joke isn't it.
Outlook:
Trading performance continued to build steadily throughout the year, materially ahead of initial expectations. This trend has continued into the new year. January 2023 was a record month, both for lending demand and for online retail sales, the value of which reached £1m in a single month for the first time. As at the end of February 2023 the pledge book had seen further growth and stood atc. £104m. We also continue to see strong demand for our FX services. We continue to believe that FX represents a growth opportunity for the Group.
What are peeps expecting?
Added to my position.
Read across from HAT Prelims 7/3/23
Trading performance continued to build steadily throughout the year, materially ahead of initial expectations. This trend has continued into the new year. January 2023 was a record month, both for lending demand and for online retail sales, the value of which reached £1m in a single month for the first time. As at the end of February 2023 the pledge book had seen further growth and stood atc. £104m. We also continue to see strong demand for our FX services. We continue to believe that FX represents a growth opportunity for the Group.
Next month, RFX has a TU, I'm expecting it to be bulging.
Perfect environment for RFXC to thrive.
Gents (I assume), keep it civilised.
We've seen the rerate at Genincode. Absolutely no reason why VRCI is not next. In fact, IMO, VRCI is closer to commercialisation.
Completely mispriced.
My bad - Chris Mills invested at 35p ! Not 30p
Still...SP is a complete p*take.
Plenty of cash still in the kitty.
Market Cap £12.77m
Enterprise Value -£289.81k
Per Stocko.
Christopher Mills of Harwood Cap invested at 30p last year.
Current SP is a complete p* take.
It is obvious that management know that the clinical data, which we all are waiting for by the end of this Q, is going to hugely positive and validation of their main product.
Tons of runway right through into mid part of 2024 - if I'm not mistaken.
II appears to have bought in with c£600k in total.
SP has bowed up since.
Possibly, this could be the bottom, at the time of writing?
Looks like sells - where was their elixir when they most needed it?
Richly deserved LTIP for some outstanding stewardship and most excellent SP performance for shareholders. Thanks management!
https://www.theguardian.com/business/2023/feb/22/uk-inflation-could-fall-below-2-citi-forecasts
If the prediction in this article pans out - MAB1 will be extremely busy again.
Gervais Williams in in at 45p - top stock selector.
Must be the sexiness of this industry.
Very appealing.
Surprising versality by ELIX - meeting upgraded expectations + Q1 ahead of expec - incredible performance.
Must be highly rated by their clients.
Spate of bad news around management consultancy yet they are performing so well. Respect!
A £1.7mn raise - down c38% - bit steep!
I did find it surprising why peeps were so bullish on this when it was at its highs.
45p - I'm in.
From my brief glance - market has shown indifference to such deals - look at C4XD or have I got the wrong end of the stick?
Results out tomorrow.
CEO has clearly stated that they will hit top end of analyst expectations in Aug 22
Guidance reiterated in mid-Nov 22 (1.5 months prior to YE)
IF exchange rate is similar to levels at the time of the August presentation, CEO implied that the results will exceed.
Exchange rates of USD to GBP are similar at the YE to Aug presentation.
c90% B2B vs 10% B2C.
Re-opening of China, re-emergence of travel in H2, 2 Prime Amazon Events (July + Oct 22) + 8% price rise in VMS division = recovery of VMS division.
60% of debt is hedged with swaps.
Appetite of film and audio production insatiable for their products - look at ZOO + ADF - they serve all companies / studios producing film and audio.
Typically H1:H2 is a minimum 48:52 split. If so, PBT will be at least £56.25mn - I would say nearer to £60mn PBT
Famous last words - this company is materially underpriced. IMO, company will not only hit top end of expectations but exceed. GL for tomorrow. Guillotine out! DYOR.
They should have released TU around early Feb as per 2022 rather than a response to the drop...
GL.
Sold out a few weeks ago at 520p.
It takes two to tango.
I had gone to the conclusion that peeps would not be willing to pay a premium for high growth. Therefore, minimal upside.
Not going to rain on the parade anymore.
Long term wise - ELIX is a winner. Short term wise - I do not know.
Or are you CNICal towards divies?
:)